Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Apr 12;2(6):563-71.
doi: 10.1016/j.ebiom.2015.04.006. eCollection 2015 Jun.

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

Yang Shen  1 , Ya-Kai Fu  1 , Yong-Mei Zhu  1 , Yin-Jun Lou  2 , Zhao-Hui Gu  1 , Jing-Yi Shi  1 , Bing Chen  1 , Chao Chen  1 , Hong-Hu Zhu  3 , Jiong Hu  1 , Wei-Li Zhao  1 , Jian-Qing Mi  1 , Li Chen  1 , Hong-Ming Zhu  1 , Zhi-Xiang Shen  1 , Jie Jin  2 , Zhen-Yi Wang  1 , Jun-Min Li  1 , Zhu Chen  1 , Sai-Juan Chen  1
Affiliations
Multicenter Study

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

Yang Shen et al. EBioMedicine. .

Abstract

Background: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to 90%. Nevertheless, about 15% of APL patients still get early death or relapse. We performed this study to address the possible impact of additional gene mutations on the outcome of APL.

Methods: We included a consecutive series of 266 cases as training group, and then validated the results in a testing group of 269 patients to investigate the potential prognostic gene mutations, including FLT3-ITD or -TKD, N-RAS, C-KIT, NPM1, CEPBA, WT1, ASXL1, DNMT3A, MLL (fusions and PTD), IDH1, IDH2 and TET2.

Results: More high-risk patients (50.4%) carried additional mutations, as compared with intermediate- and low-risk ones. The mutations of epigenetic modifier genes were associated with poor prognosis in terms of disease-free survival in both training (HR = 6.761, 95% CI 2.179-20.984; P = 0.001) and validation (HR = 4.026, 95% CI 1.089-14.878; P = 0.037) groups. Sanz risk stratification was associated with CR induction and OS.

Conclusion: In an era of ATRA/ATO treatment, both molecular markers and clinical parameter based stratification systems should be used as prognostic factors for APL.

Keywords: Acute promyelocytic leukemia; Epigenetic; Mutation; Prognosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Correlation between gene mutations and clinical risk groups. High-risk patients contained more mutations additional to PML–RARα (50.4%, 66/131) as compared with intermediate- (25.0%, 62/248, P < 0.001) and low-risk (23.1%, 36/156, P < 0.001) groups.
Fig. 2
Fig. 2
Kaplan–Meier curves for overall survival (OS) and disease-free survival (DFS) according to Sanz's risk stratification in univariate analysis. (A, B) OS and DFS of different risk groups in training group. (C, D) OS and DFS of different risk groups in validation group.
Fig. 3
Fig. 3
Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to EMG mutational status in univariate analysis. (A, B) OS and DFS of patients with EMG mutations in training group. (C, D) OS and DFS of patients with EMG mutations in validation group.
Fig. 4
Fig. 4
Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to FLT3 mutational status in univariate analysis. (A, B) OS and DFS of patients with FLT3 mutations in training group. (C, D) OS and DFS of patients with FLT3 mutations in validation group.
See this image and copyright information in PMC

Comment in

References

    1. Au W.Y., Lam C.C., Ma E.S., Man C., Wan T., Kwong Y.L. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features. Hum. Pathol. 2001;32(1):126–129. - PubMed
    1. Avvisati G., Lo Coco F., Diverio D. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390–1398. - PubMed
    1. Bashey A., Gill R., Levi S. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis. Blood. 1992;79(4):981–989. - PubMed
    1. Beitinjaneh A., Jang S., Roukoz H., Majhail N.S. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk. Res. 2010;34(7):831–836. - PubMed
    1. Bowen D.T., Frew M.E., Hills R. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113–2119. - PubMed

Publication types

MeSH terms

LinkOut - more resources